The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients

Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients

March 27, 2020 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The week of March 16, reports of hydroxychloroquine (HCQ) shortages began to circulate around the U.S. following a sudden surge in interest regarding the drug’s potential use as a therapy for COVID-19. As clinical trials are launched to investigate this and other treatments already approved for rheumatic diseases, rheumatologists and their patients are worried about the availability of HCQ to fill existing prescriptions for lupus and other diseases.

You Might Also Like
  • What’s a Rheumatologist? Rheumatic Disease Awareness Month spurs support for rheumatology patients & professionals
  • U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
Also By This Author
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease

On March 20, the ACR co-authored a letter to Vice President Mike Pence, head of the U.S. COVID-19 Task Force, calling for the U.S. Food and Drug Administration (FDA) to monitor and report any drug shortages and ensure HCQ supplies are protected for patients with autoimmune diseases. The letter co-authors were the Lupus Foundation of America, the American Academy of Dermatology and the Arthritis Foundation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On March 20, ACR President-Elect David Karp, MD, PhD, was interviewed about shortage concerns by The New York Times.1 The ACR urges members to report any local drug shortages to the FDA at [email protected].

Old Drug, New Interest
How did this medication used to treat systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome and other diseases attract worldwide interest as a possible COVID-19 therapy? On March 17, the International Journal of Antimicrobial Agents published early data from an open-label, non-randomized, 36-patient clinical trial conducted at a hospital in Marseilles, France, investigating HCQ used alone or in combination with the antibiotic azithromycin to treat severe COVID-19. The study was widely shared on social media and even mentioned by President Donald Trump in his daily press briefing on March 19.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Ever since the release of the French study examining the utility of HCQ in COVID-19 patients, interest in HCQ skyrocketed to the point that its supply has evaporated,” says Alfred Kim, MD, PhD, a rheumatologist and assistant professor of medicine at the Washington University School of Medicine, St. Louis. “In the St. Louis region, right after the study came out, most of the pharmacies had several hundred pills of HCQ in stock, but their suppliers were either out or had very low stock. Starting Monday, we have had increasing number of patients who cannot get their prescriptions refilled.”

Dawn Smith-Popielski, a patient in St. Louis who takes HCQ for Sjögren’s syndrome, says she is close to needing a refill and is worried about its availability through her mail-order pharmacy.

“I am more alarmed by the response of friends on Facebook suddenly talking about HCQ and wondering how they can get it. These are people who don’t have an autoimmune disease and do not necessarily know that taking this drug requires regular monitoring with lab tests and eye exams,” she says. Ms. Smith-Popielski says she had severe ophthalmologic symptoms until starting HCQ two years ago.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, Drug shortage, HCQ, Hydroxychloroquine (HCQ)

You Might Also Like:
  • What’s a Rheumatologist? Rheumatic Disease Awareness Month spurs support for rheumatology patients & professionals
  • U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Novartis to Test Efficacy of Old Malaria Drug Against COVID-19

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)